{"title":"肾功能受损的 2 型糖尿病患者的血清 L C3-II 水平。","authors":"Shahab Ahmed Salıh Gezh , Koksal Deveci , Hakan Sivgin , Figen Guzelgul","doi":"10.1016/j.cyto.2024.156683","DOIUrl":null,"url":null,"abstract":"<div><p>This study was designed to evaluate serum LC3-II, BCL-2, IL-1β, TGF-β1, and podocin levels in.</p><p>type 2 diabetes (T2DM) patients with renal dysfunction.</p></div><div><h3>Materials</h3><p>176 Turkish subjects were enrolled, of whom 26 were healthy, and 150 had T2DM. Patients.</p><p>were classified according to albumin urea ratio: 88 patients had macroalbuminuria, 20.</p><p>patients had microalbuminuria, and 42 had normoalbuminuria. T2DM patients were also.</p><p>classified into three groups according to proteinuria and eGFR stages.</p></div><div><h3>Results</h3><p>Increased serum LC3-II levels in patients with T2DM with increased urinary albumin.</p><p>extraction and impaired renal functions. There was a strong relationship between serum.</p><p>LC3-II levels and serum BCL-2, IL-1β, TGF-β1, and Podocin levels. The efficiency of LC3-</p><p>II as a diagnostic biomarker in the differential diagnosis of DM patients with.</p><p>macroproteinuria from DM patients with normoproteinuria was 75.4%.</p></div><div><h3>Conclusions</h3><p>It was thought that increased serum LC3-II levels in T2DM patients with impaired renal.</p><p>functions may cause renal podocyte damage. In these patients, serum LC3-II levels can be.</p><p>evaluated as a new biomarker to follow the development of renal damage.</p></div>","PeriodicalId":297,"journal":{"name":"Cytokine","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Serum L C3-II levels in type 2 diabetic patients with impaired renal functions\",\"authors\":\"Shahab Ahmed Salıh Gezh , Koksal Deveci , Hakan Sivgin , Figen Guzelgul\",\"doi\":\"10.1016/j.cyto.2024.156683\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This study was designed to evaluate serum LC3-II, BCL-2, IL-1β, TGF-β1, and podocin levels in.</p><p>type 2 diabetes (T2DM) patients with renal dysfunction.</p></div><div><h3>Materials</h3><p>176 Turkish subjects were enrolled, of whom 26 were healthy, and 150 had T2DM. Patients.</p><p>were classified according to albumin urea ratio: 88 patients had macroalbuminuria, 20.</p><p>patients had microalbuminuria, and 42 had normoalbuminuria. T2DM patients were also.</p><p>classified into three groups according to proteinuria and eGFR stages.</p></div><div><h3>Results</h3><p>Increased serum LC3-II levels in patients with T2DM with increased urinary albumin.</p><p>extraction and impaired renal functions. There was a strong relationship between serum.</p><p>LC3-II levels and serum BCL-2, IL-1β, TGF-β1, and Podocin levels. The efficiency of LC3-</p><p>II as a diagnostic biomarker in the differential diagnosis of DM patients with.</p><p>macroproteinuria from DM patients with normoproteinuria was 75.4%.</p></div><div><h3>Conclusions</h3><p>It was thought that increased serum LC3-II levels in T2DM patients with impaired renal.</p><p>functions may cause renal podocyte damage. In these patients, serum LC3-II levels can be.</p><p>evaluated as a new biomarker to follow the development of renal damage.</p></div>\",\"PeriodicalId\":297,\"journal\":{\"name\":\"Cytokine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-06-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cytokine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1043466624001868\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytokine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043466624001868","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
期刊介绍：
The journal Cytokine has an open access mirror journal Cytokine: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review.
* Devoted exclusively to the study of the molecular biology, genetics, biochemistry, immunology, genome-wide association studies, pathobiology, diagnostic and clinical applications of all known interleukins, hematopoietic factors, growth factors, cytotoxins, interferons, new cytokines, and chemokines, Cytokine provides comprehensive coverage of cytokines and their mechanisms of actions, 12 times a year by publishing original high quality refereed scientific papers from prominent investigators in both the academic and industrial sectors.
We will publish 3 major types of manuscripts:
1) Original manuscripts describing research results.
2) Basic and clinical reviews describing cytokine actions and regulation.
3) Short commentaries/perspectives on recently published aspects of cytokines, pathogenesis and clinical results.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
